A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer
Soluble cytokines, especially HGF, have certain clinical value in immunotherapy combination therapy and prognosis of NSCLC patients and are worthy of validation in a larger prospective cohort and exploration of their potential mechanisms.
Authors
- Yuan Gao (ORCID: https://orcid.org/0000-0002-0670-9104)
- Minghang Zhang
- Xiaomi Li (ORCID: https://orcid.org/0000-0002-6386-6640)
- Ying Wang (ORCID: https://orcid.org/0000-0002-1444-5778)
- Mingming Hu (ORCID: https://orcid.org/0000-0003-0021-0633)
- Shaofa Xu (ORCID: https://orcid.org/0000-0003-2081-6608)
- Yanxia Liu (ORCID: https://orcid.org/0000-0003-1479-4043)
- Tongmei Zhang (ORCID: https://orcid.org/0000-0003-4271-3773)
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Beijing Chest Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1093/oncolo/oyaf306
- Citations
- 1
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05